Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonists used to treat a range of metabolic conditions. It has fundamentally reshaped the medical landscape for type 2 diabetes and chronic weight management.
Mechanism of Action: The GLP-1 Master Mimic
Semaglutide’s mechanism of action is rooted in its ability to mimic the naturally occurring GLP-1 hormone, with which it shares a 94% structural homology. As a single-target agonist, Semaglutide activates GLP-1 receptors located in the pancreas, gastrointestinal tract, and brain. This activation triggers a cascade of physiological effects that collectively improve metabolic control. In the pancreas, it enhances insulin secretion in a glucose-dependent manner while simultaneously suppressing glucagon release, which helps reduce the liver’s production of glucose. In the stomach, it slows the rate of gastric emptying, promoting a lasting feeling of fullness and thereby reducing overall food intake. Two specific structural modifications also give Semaglutide a prolonged half-life, allowing for its convenient once-weekly dosing schedule.
The Foundational SUSTAIN and STEP Trials
Semaglutide’s journey began with the SUSTAIN series of trials, which established its efficacy and safety for glycemic control in adults with type 2 diabetes. These studies laid the groundwork for its subsequent application in weight management. The focus then shifted to the STEP trials, which specifically investigated Semaglutide’s role in chronic weight management in individuals with obesity. These trials demonstrated the powerful weight-loss potential of a 2.4 mg dose, leading to the FDA approval of Wegovy for this indication.
Recent research continues to push the boundaries of what is possible with Semaglutide. New findings from the Phase 3b STEP UP trial explored a higher 7.2 mg dose. In this study, participants on the 7.2 mg dose achieved a superior average weight loss of 20.7% over 72 weeks compared to the 17.5% reduction seen with the 2.4 mg dose. This demonstrates that the therapeutic potential of Semaglutide is still being optimized and reinforces its place as a leading therapy.
Cardiovascular and Metabolic Outcomes
Initial research on GLP-1 agonists was primarily focused on their effects on blood sugar. However, the SUSTAIN 6 and SELECT cardiovascular outcomes trials revealed a profound, unexpected benefit. These studies were designed to demonstrate that Semaglutide did not increase cardiovascular risk. Instead, they showed a significant reduction in the incidence of major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. This revelation transformed the understanding of this class of drugs, establishing them not just as treatments for diabetes and obesity, but as powerful cardioprotective agents. This finding demonstrates the dynamic nature of scientific inquiry, where a primary research question can be answered in a way that reveals an even more significant and far-reaching therapeutic benefit.
Safety Profile and Limitations
While Semaglutide is generally well-tolerated, a balanced overview of its safety profile is crucial. The most common side effects are gastrointestinal, including nausea, vomiting, abdominal pain, and diarrhea. These effects are often dose-dependent and most prevalent during the initial titration period. More serious, albeit rare, side effects that have been reported include acute pancreatitis, gallbladder disorders, and acute kidney injury, which is often secondary to dehydration from gastrointestinal issues. Semaglutide also carries a boxed warning about the risk of thyroid C-cell tumors, a risk identified in rodent studies. The FDA has also issued warnings about the risks associated with unapproved, compounded versions of Semaglutide, citing hundreds of adverse event reports linked to these unregulated products.
Works Cited
Tirzepatide vs. Semaglutide: Similarities and Differences – Healthline, accessed September 23, 2025, https://www.healthline.com/health/tirzepatide-vs-semaglutide
Semaglutide – StatPearls – NCBI Bookshelf, accessed September 23, 2025, https://www.ncbi.nlm.nih.gov/books/NBK603723/
Higher-Dose Semaglutide (7.2 mg) Demonstrates Superior Weight Loss in STEP UP Trial, accessed September 23, 2025, https://trial.medpath.com/news/e3fe19cfbae583eb/semaglutide-7-2-mg-shows-superior-weight-loss-in-step-up-trial
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular …, accessed September 23, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7064975/
FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, accessed September 23, 2025, https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss